Design, Synthesis, and Biological Evaluation of Enantiomeric β-N-Acetylhexosaminidase Inhibitors LABNAc and DABNAc as Potential Agents against Tay-Sachs and Sandhoff Disease

Combating glycolipid storage disorders: LABNAc was prepared in an efficient 11‐step procedure from D‐lyxonolactone. The enantiomer DABNAc was also prepared from L‐lyxonolactone. Preliminary cellular studies indicate that these compounds may find utility as chemical chaperones for the treatment of Tay‐Sachs and Sandhoff diseases. N‐Acetylhexosaminidases are of considerable importance in mammals and are involved in various significant biological processes. In humans, deficiencies of these enzymes in the lysosome, resulting from inherited genetic defects, cause the glycolipid storage disorders Tay‐Sachs and Sandhoff diseases. One promising therapy for these diseases involves the use of β‐N‐acetylhexosaminidase inhibitors as chemical chaperones to enhance the enzyme activity above sub‐critical levels. Herein we describe the synthesis and biological evaluation of a potent inhibitor, 2‐acetamido‐1,4‐imino‐1,2,4‐trideoxy‐L‐arabinitol (LABNAc), in a high‐yielding 11‐step procedure from D‐lyxonolactone. The N‐benzyl and N‐butyl analogues were also prepared and found to be potent inhibitors. The enantiomers DABNAc and NBn‐DABNAc were synthesised from L‐lyxonolactone, and were also evaluated. The L‐iminosugar LABNAc and its derivatives were found to be potent noncompetitive inhibitors of some β‐N‐acetylhexosaminidases, while the D‐iminosugar DABNAc and its derivatives were found to be weaker competitive inhibitors. These results support previous work postulating that D‐iminosugar mimics inhibit D‐glycohydrolases competitively, and that their corresponding L‐enantiomers show noncompetitive inhibition of these enzymes. Molecular modelling studies confirm that the spatial organisation in enantiomeric inhibitors leads to a different overlay with the monosaccharide substrate. Initial cell‐based studies suggest that NBn‐LABNAc can act as a chemical chaperone to enhance the deficient enzyme's activity to levels that may cause a positive pharmacological effect. LABNAc, NBn‐LABNAc, and NBu‐LABNAc are potent and selective inhibitors of β‐N‐acetylhexosaminidase and may be useful as therapeutic agents for treating adult Tay‐Sachs and Sandhoff diseases. Combating glycolipid storage disorders: LABNAc was prepared in an efficient 11‐step procedure from D‐lyxonolactone. The enantiomer DABNAc was also prepared from L‐lyxonolactone. Preliminary cellular studies indicate that these compounds may find utility as chemical chaperones for the treatment of Tay‐Sachs and Sandhoff diseases.